Lumos Diagnostics Clears All Debt to Focus Capital on US FebriDx Launch
Lumos closes A$5.0 million loan facility and returns to a debt-free position
Lumos Diagnostics (ASX:LDX) has closed out its A$5.0 million secured Loan Facility with major shareholders Tenmile Ventures Pty Ltd and Ryder Capital Management Pty Ltd, effective 2 July 2026.
The Company now carries no debt, with all lender security interests released. The facility was repaid in full following the receipt of A$20.0 million in placement proceeds in April 2026.
For the point-of-care diagnostics firm, the outcome signals a strengthened balance sheet, freeing management to focus on the U.S. commercialisation of its flagship test, FebriDx®.
When big ASX news breaks, our subscribers know first
How the loan facility was repaid and unwound
The secured Loan Facility was established on 9 September 2025 to provide working capital flexibility while Lumos progressed towards a CLIA waiver from the U.S. FDA for FebriDx®.
Lumos drew A$1.0 million of the total, leaving A$4.0 million unused. Following the completion and receipt of the A$20.0 million placement proceeds in April 2026, the outstanding balance was repaid in full, including accrued interest, as previously advised at the time of the capital raise.
As at the date of the announcement, the Company holds no debt, and the security interests held by the lenders under the facility have now been released.
| Facility element | Detail |
|---|---|
| Facility size | A$5.0 million (secured) |
| Lenders | Tenmile Ventures, Ryder Capital Management |
| Established | 9 September 2025 |
| Amount drawn | A$1.0 million |
| Amount unused | A$4.0 million |
| Repaid via | A$20.0 million placement (April 2026) |
| Current debt | Nil |
CEO Commentary
“The Company sincerely appreciates the financial support provided by Tenmile and Ryder Capital, with this loan provided as a bridge while Lumos progressed its application toward the transformative and successful granting of CLIA waiver for FebriDx®. Now well-funded, Lumos was in a position to close out this loan, release the security and accelerate the U.S. commercialisation of FebriDx®,” said Doug Ward, Chief Executive Officer of Lumos Diagnostics.
The next major ASX story will hit our subscribers first
What a debt-free balance sheet means for investors
A secured loan facility is a borrowing arrangement backed by a company’s assets, giving lenders a claim over those assets if the debt is not repaid. When security interests are released, that claim is removed, and the lenders no longer hold any charge over company assets.
For a growth-stage diagnostics company, returning to a debt-free position matters. Repaying the facility removes ongoing interest costs and financing risk from the balance sheet.
Being well-funded after the April 2026 placement allows management to direct capital toward its stated strategic priority: the U.S. commercialisation of FebriDx®. A cleaner balance sheet also improves flexibility as the Company approaches the FebriDx® commercial ramp.
The WellStreet Urgent Care expansion, which extended FebriDx deployment from a single pilot to 43 locations across three U.S. regions with a full 163-site network targeted within 6-12 months, represents one of the first concrete signals of the commercial traction the debt-free balance sheet is intended to accelerate.
FebriDx® is a rapid, point-of-care test, and the facility was designed to bridge Lumos towards the granting of its U.S. FDA CLIA waiver, a milestone referenced in the announcement.
The FDA CLIA waiver for FebriDx, granted on 27 March 2026, expanded the test’s addressable market 15-fold to over US$1.0 billion by opening access to more than 300,000 U.S. point-of-care locations that had previously been out of reach under the moderate-complexity classification.
With the loan closed and security released, Lumos enters its next phase debt-free and focused on advancing the U.S. commercialisation of FebriDx®.
Stay Ahead on ASX Healthcare News
Big News Blast delivers FREE breaking ASX healthcare announcements to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already getting the edge on market-moving news. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment they drop.